Everolimus drug-eluting stent placement in infants may be associated with severe hypertriglyceridemia, necessitating close monitoring of serum triglyceride levels.
Answers are grounded in this paper and cite their sources.
May warrant triglyceride monitoring after everolimus-eluting stent placement in infants; leaves open causality and need for prospective data.
We report a case of severe hypertriglyceridemia associated with an everolimus drug-eluting stent in an infant with pulmonary vein stenosis. We review from current literature the mechanisms by which everolimus may cause dyslipidaemia, pharmacokinetics of everolimus in drug-eluting stents, and treatments of hypertriglyceridemia. This case demonstrates the need to closely monitor serum triglyceride levels after everolimus drug-eluting stent placement in infants.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: